STRATEGIES FOR IDENTIFYING PREDICTIVE BIOMARKERS AND SUBGROUPS WITH ENHANCED TREATMENT EFFECT IN CLINICAL TRIALS USING SIDES

被引:55
|
作者
Lipkovich, Ilya [1 ]
Dmitrienko, Alex [1 ]
机构
[1] Quintiles, Durham, NC 27703 USA
关键词
Biomarker discovery; Predictive biomarkers; SIDES method; Subgroup identification; Variable importance; IDENTIFICATION; FRAMEWORK; SIGNATURE;
D O I
10.1080/10543406.2013.856024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Several approaches to identification of predictive biomarkers and subgroups of patients with enhanced treatment effect have been proposed in the literature. The SIDES method introduced in Lipkovich et al. (2011) adopts a recursive partitioning algorithm for screening treatment-by-biomarker interactions. This article introduces an improved biomarker discovery/subgroup search method (SIDEScreen). The SIDEScreen method relies on a two-stage procedure that first selects a small number of biomarkers with the highest predictive ability based on an appropriate variable importance score and then identifies subgroups with enhanced treatment effect based on the selected biomarkers. The two-stage approach helps increase the signal-to-noise ratio by screening out noninformative biomarkers. We evaluate operating characteristics of the standard SIDES method and two SIDEScreen procedures based on fixed and adaptive screens. Our main finding is that the adaptive SIDEScreen method is a more flexible biomarker discovery tool than SIDES and it better handles multiplicity in complex subgroup search problems. The methods presented in the article are illustrated using a clinical trial example.
引用
收藏
页码:130 / 153
页数:24
相关论文
共 50 条
  • [11] Using biomarkers in clinical trials in ophthalmology
    Beuerman, R.
    ACTA OPHTHALMOLOGICA, 2017, 95
  • [12] Sample size and threshold estimation for clinical trials with predictive biomarkers
    Mackey, Howard M.
    Bengtsson, Thomas
    CONTEMPORARY CLINICAL TRIALS, 2013, 36 (02) : 664 - 672
  • [13] Adaptive enrichment design for randomised clinical trials with predictive biomarkers
    Parashar, Deepak
    Peneva, Iliana
    Stallard, Nigel
    TRIALS, 2017, 18
  • [14] Identifying research priorities for effective retention strategies in clinical trials
    Kearney, Anna
    Daykin, Anne
    Shaw, Alison R. G.
    Lane, Athene J.
    Blazeby, Jane M.
    Clarke, Mike
    Williamson, Paula
    Gamble, Carrol
    TRIALS, 2017, 18
  • [15] Identifying research priorities for effective retention strategies in clinical trials
    Anna Kearney
    Anne Daykin
    Alison R. G. Shaw
    Athene J. Lane
    Jane M. Blazeby
    Mike Clarke
    Paula Williamson
    Carrol Gamble
    Trials, 18
  • [16] Identifying Strategies in Patient Recruitment for Acute Stroke Clinical Trials
    Ali, Mehnaaz
    Terry, John B.
    Shoen, Angie
    Friedman, Loren
    NEUROLOGY, 2020, 94 (15)
  • [17] Using biomarkers prospectively in adaptive clinical trials
    Donald A Berry
    Trials, 12 (Suppl 1)
  • [18] Randomized Phase II Cancer Clinical Trials to Validate Predictive Biomarkers
    Zhang, Baoshan
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Jung, Sin-Ho
    BIOMEDICINES, 2024, 12 (10)
  • [19] Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials
    Shi, Qian
    Mandrekar, Sumithra J.
    Sargent, Daniel J.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (03) : 356 - 362
  • [20] Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers
    Shih, Weichung Joe
    Lin, Yong
    STATISTICS IN MEDICINE, 2018, 37 (05) : 687 - 709